Cargando…
Clinical implications of hedgehog signaling pathway inhibitors
Hedgehog was first described in Drosophila melanogaster by the Nobel laureates Eric Wieschaus and Christiane Nüsslein-Volhard. The hedgehog (Hh) pathway is a major regulator of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and Carcinogenesis. The first link of Hh signa...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137255/ https://www.ncbi.nlm.nih.gov/pubmed/21192841 http://dx.doi.org/10.5732/cjc.010.10540 |
_version_ | 1782208278569156608 |
---|---|
author | Liu, Hailan Gu, Dongsheng Xie, Jingwu |
author_facet | Liu, Hailan Gu, Dongsheng Xie, Jingwu |
author_sort | Liu, Hailan |
collection | PubMed |
description | Hedgehog was first described in Drosophila melanogaster by the Nobel laureates Eric Wieschaus and Christiane Nüsslein-Volhard. The hedgehog (Hh) pathway is a major regulator of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and Carcinogenesis. The first link of Hh signaling to cancer was established through studies of a rare familial disease, Gorlin syndrome, in 1996. Follow-up studies revealed activation of this pathway in basal cell carcinoma, medulloblastoma and, leukemia as well as in gastrointestinal, lung, ovarian, breast, and prostate cancer. Targeted inhibition of Hh signaling is now believed to be effective in the treatment and prevention of human cancer. The discovery and synthesis of specific inhibitors for this pathway are even more exciting. In this review, we summarize major advances in the understanding of Hh signaling pathway activation in human cancer, mouse models for studying Hh-mediated Carcinogenesis, the roles of Hh signaling in tumor development and metastasis, antagonists for Hh signaling and their clinical implications. |
format | Online Article Text |
id | pubmed-3137255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Sun Yat-sen University Cancer Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-31372552011-07-15 Clinical implications of hedgehog signaling pathway inhibitors Liu, Hailan Gu, Dongsheng Xie, Jingwu Chin J Cancer Review Hedgehog was first described in Drosophila melanogaster by the Nobel laureates Eric Wieschaus and Christiane Nüsslein-Volhard. The hedgehog (Hh) pathway is a major regulator of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and Carcinogenesis. The first link of Hh signaling to cancer was established through studies of a rare familial disease, Gorlin syndrome, in 1996. Follow-up studies revealed activation of this pathway in basal cell carcinoma, medulloblastoma and, leukemia as well as in gastrointestinal, lung, ovarian, breast, and prostate cancer. Targeted inhibition of Hh signaling is now believed to be effective in the treatment and prevention of human cancer. The discovery and synthesis of specific inhibitors for this pathway are even more exciting. In this review, we summarize major advances in the understanding of Hh signaling pathway activation in human cancer, mouse models for studying Hh-mediated Carcinogenesis, the roles of Hh signaling in tumor development and metastasis, antagonists for Hh signaling and their clinical implications. Sun Yat-sen University Cancer Center 2011-01 /pmc/articles/PMC3137255/ /pubmed/21192841 http://dx.doi.org/10.5732/cjc.010.10540 Text en Chinese Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission. |
spellingShingle | Review Liu, Hailan Gu, Dongsheng Xie, Jingwu Clinical implications of hedgehog signaling pathway inhibitors |
title | Clinical implications of hedgehog signaling pathway inhibitors |
title_full | Clinical implications of hedgehog signaling pathway inhibitors |
title_fullStr | Clinical implications of hedgehog signaling pathway inhibitors |
title_full_unstemmed | Clinical implications of hedgehog signaling pathway inhibitors |
title_short | Clinical implications of hedgehog signaling pathway inhibitors |
title_sort | clinical implications of hedgehog signaling pathway inhibitors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137255/ https://www.ncbi.nlm.nih.gov/pubmed/21192841 http://dx.doi.org/10.5732/cjc.010.10540 |
work_keys_str_mv | AT liuhailan clinicalimplicationsofhedgehogsignalingpathwayinhibitors AT gudongsheng clinicalimplicationsofhedgehogsignalingpathwayinhibitors AT xiejingwu clinicalimplicationsofhedgehogsignalingpathwayinhibitors |